For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240122:nRSV4298Aa&default-theme=true
RNS Number : 4298A Seed Innovations Limited 22 January 2024
22 January 2024
SEED Innovations Limited
("SEED" or the "Company")
CEO Presenting at Proactive One2One Investor Forum
SEED Innovations Ltd, the AIM-quoted company investment company providing
shareholders with exposure to early-stage health, wellness and medical
cannabis companies to which, in normal circumstances, they have limited access
to, is pleased to announce that it will be participating in the Proactive
One2One Investor Forum at the Chesterfield Mayfair Hotel in London from 6 pm
on Thursday 25 January 2024.
The in-person event will allow interested investors to learn more about the
Company's investment opportunity, strategy, and market drivers.
The agenda includes a presentation by Ed McDermott, CEO of Seed Innovations,
to be followed by a short Q&A session.
The event will also be available to view afterwards on Proactive's YouTube
channel and the Company's social media: https://twitter.com/SEEDInnov
(https://twitter.com/SEEDInnov)
For further details and to register your attendance, please click the
following link:
https://www.proactiveinvestors.co.uk/register/event_details/437
(https://www.proactiveinvestors.co.uk/register/event_details/437)
-Ends-
For further information on the Company please visit: www.seedinnovations.co
(http://www.seedinnovations.co/) or contact:
Ed McDermott SEED Innovations Ltd E: info@seedinnovations.co
Lance de Jersey
James Biddle Beaumont Cornish Limited, T: (0)20 7628 3396
Roland Cornish Nomad
Isabella Pierre Shard Capital Partners LLP T: (0)20 7186 9927
Damon Heath Broker
Ana Ribeiro St Brides Partners Ltd, E: seed@stbridespartners.co.uk
Isabelle Morris Financial PR
Notes
Seed Innovations Ltd
SEED Innovations is an AIM quoted investment company focused primarily on
disruptive high growth life sciences and technology businesses particularly
within the medical cannabis arena. The Company's strategy is to identify
early-stage opportunities that have an upcoming investment catalyst and grow
its portfolio in terms of value whilst limiting the number of investee
companies to a level where relevant time can be devoted to each.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRABTMTTMTMTMLI